Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis

[1] Michot JM(2016)Immune-related adverse events with immune checkpoint blockade: a comprehensive review Eur J Cancer 54 139-148

[2] Bigenwald C(2018)Immune-related adverse events associated with immune checkpoint blockade N Engl J Med 378 158-168

[3] Champiat S(2020)Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation Ann Rheum Dis 79 332-338

[4] Collins M(2019)Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer Autoimmun Rev 18 805-813

[5] Carbonnel F(2018)Rheumatic immune-related adverse events from cancer immunotherapy Nat Rev Rheumatol 14 569-579

[6] Postel-Vinay S(2019)Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients Arthritis Rheumatol 71 468-475

[7] Berdelou A(2010)2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Ann Rheum Dis 69 1580-1588

[8] Varga A(2018)Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study Ann Rheum Dis 77 393-398

[9] Bahleda R(2017)Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab Ann Rheum Dis 76 43-50

[10] Hollebecque A(2013)Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity Autoimmun Rev 12 1091-1100

[1] Michot JM(2016)Immune-related adverse events with immune checkpoint blockade: a comprehensive review Eur J Cancer 54 139-148

[2] Bigenwald C(2018)Immune-related adverse events associated with immune checkpoint blockade N Engl J Med 378 158-168

[3] Champiat S(2020)Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation Ann Rheum Dis 79 332-338

[4] Collins M(2019)Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer Autoimmun Rev 18 805-813

[5] Carbonnel F(2018)Rheumatic immune-related adverse events from cancer immunotherapy Nat Rev Rheumatol 14 569-579

[6] Postel-Vinay S(2019)Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients Arthritis Rheumatol 71 468-475

[7] Berdelou A(2010)2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Ann Rheum Dis 69 1580-1588

[8] Varga A(2018)Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study Ann Rheum Dis 77 393-398

[9] Bahleda R(2017)Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab Ann Rheum Dis 76 43-50

[10] Hollebecque A(2013)Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity Autoimmun Rev 12 1091-1100